High-resolution deep mutational scanning of the melanocortin-4 receptor enables target characterization for drug discovery
eLife · 09.04.2025 · 13
DOI: 10.7554/elife.104725 ↗Kurz gefasst
Fachartikel in der Zeitschrift eLife, online erschienen am 09.04.2025. Verfasst von Conor J Howard und 17 weiteren Autor:innen. Beteiligte Einrichtung: Octant, Inc, Emeryville, United States. Hauptthemen laut MEDLINE: Receptor, Melanocortin, Type 4, Drug Discovery. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 90 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, National Institute of General Medical Sciences.
Abstract (Originalsprache)
Deep Mutational Scanning (DMS) is an emerging method to systematically test the functional consequences of thousands of sequence changes to a protein target in a single experiment. Because of its utility in interpreting both human variant effects and protein structure-function relationships, it holds substantial promise to improve drug discovery and clinical development. However, applications in this domain require improved experimental and analytical methods. To address this need, we report novel DMS methods to precisely and quantitatively interrogate disease-relevant mechanisms, protein-ligand interactions, and assess predicted response to drug treatment. Using these methods, we performed a DMS of the melanocortin-4 receptor (MC4R), a G-protein-coupled receptor (GPCR) implicated in obesity and an active target of drug development efforts. We assessed the effects of >6600 single amino acid substitutions on MC4R’s function across 18 distinct experimental conditions, resulting in >20 million unique measurements. From this, we identified variants that have unique effects on MC4R-mediated Gα s - and Gα q -signaling pathways, which could be used to design drugs that selectively bias MC4R’s activity. We also identified pathogenic variants that are likely amenable to a corrector therapy. Finally, we functionally characterized structural relationships that distinguish the binding of peptide versus small molecule ligands, which could guide compound optimization. Collectively, these results demonstrate that DMS is a powerful method to empower drug discovery and development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Octant, Inc, Emeryville, United States.
- Department of Human Genetics and Department of Computational Medicine, University of California, Los Angeles, Los Angeles, United States.
- Howard Hughes Medical Institute, Chevy Chase, United States.
ORCID-Profile: Conor J Howard, Beatriz A Osuna, Eric M Jones, Leon Y Chan, Joshua S Bloom, Sriram Kosuri, Diane E Dickel, Nathan B Lubock
Förderung
- NIGMS NIH HHS
- National Institute of General Medical Sciences
Zitieren
APA
Howard, C. J., Abell, N. S., Osuna, B. A., Jones, E. M., Chan, L. Y., Chan, H., Artis, D. R., Asfaha, J. B., Bloom, J. S., Cooper, A. R., Liao, A., Mahdavi, E., Mohammed, N., Su, A. L., Uribe, G. A., Kosuri, S., Dickel, D. E., & Lubock, N. B. (2025). High-resolution deep mutational scanning of the melanocortin-4 receptor enables target characterization for drug discovery. eLife, 13. https://doi.org/10.7554/elife.104725
Vancouver
Howard CJ, Abell NS, Osuna BA, Jones EM, Chan LY, Chan H, et al. High-resolution deep mutational scanning of the melanocortin-4 receptor enables target characterization for drug discovery. eLife. 2025;13. doi:10.7554/elife.104725
BibTeX
@article{Howard2025,
author = {Howard, Conor J and Abell, Nathan S and Osuna, Beatriz A and Jones, Eric M and Chan, Leon Y and Chan, Henry and Artis, Dean R and Asfaha, Jonathan B and Bloom, Joshua S and Cooper, Aaron R and Liao, Andrew and Mahdavi, Eden and Mohammed, Nabil and Su, Alan L and Uribe, Giselle A and Kosuri, Sriram and Dickel, Diane E and Lubock, Nathan B},
title = {High-resolution deep mutational scanning of the melanocortin-4 receptor enables target characterization for drug discovery},
journal = {eLife},
year = {2025},
volume = {13},
doi = {10.7554/elife.104725}
}
EUVIMED